Prevention of type 2 diabetes: What challenges do we have to address?

Journal of Public Health

Volumn 13, Issue 6, 2005, Pages 303-308

  Schwarz, P E H ^a   Schwarz, J ^a   Bornstein, S R ^a   Schulze, J ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Prevention; TUMAINI+; Type 2 diabetes

Indexed keywords

ACARBOSE; METFORMIN; ORAL ANTIDIABETIC AGENT; TETRAHYDROLIPSTATIN; TROGLITAZONE;

BEHAVIOR MODIFICATION; CLINICAL TRIAL; DIET; DIET THERAPY; DISEASE PREDISPOSITION; ENVIRONMENTAL FACTOR; EPIDEMIC; EXERCISE; GENETIC SUSCEPTIBILITY; GLUCOSE TOLERANCE; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; IMMOBILIZATION; INSULIN RESISTANCE; LIFESTYLE; MEDICAL CARE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; PHYSICAL ACTIVITY; PUBLIC HEALTH; REVIEW; RISK FACTOR; RISK REDUCTION; SOCIOECONOMICS;

EID: 27744441317     PISSN: 09431853     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10389-005-0131-0     Document Type: Review

References (25)

1. Alberti KG (2002) Type 2 diabetes: questions of prevention. Diabetes Voice 47(4):5
2. Azen SP, Peters RK, Berkowitz K, et al (1998) TRIPOD (TRoglitazone In the Prevention Of Diabetes): a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 19(2):217-231
3. Chiasson JL, Gomis R, Hanefeld M, et al (1998) The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 21(10):1720-1725
4. Chiasson JL, Josse RG, Gomis R, et al (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359(9323):2072-2077
5. DECODE Study Group (2003) Age- and sex-specific prevalences of diabetes and impaired glucose regulation in 13 European cohorts. Diabetes Care 26(1):61-69
6. Haffner SM (2002) Can reducing peaks prevent type 2 diabetes: implication from recent diabetes prevention trials. Int J Clin Pract Suppl (129):33-39
7. Haffner S, Taegtmeyer H (2003) Epidemic obesity and the metabolic syndrome. Circulation 108(13):1541-1545
8. King H (1998) Epidemiology of glucose intolerance and gestational diabetes in women of childbearing age. Diabetes Care 21 [Suppl 2]:B9-B13
9. Knowler WC, Barrett-Connor E, Fowler SE, et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346(6):393-403
10. Liebl A, Goertz A, Henkel B, et al (2000) Costly type 2 diabetes mellitus. Does diabetes cost 20 billion per year? (in German). MMW Fortschr Med 142(23):39-42
11. Lindstrom J, Tuomilehto J (2003) The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 26(3):725-731
12. Pan XR, Li GW, Hu YH, et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20(4):537-544
13. Sartorelli DS, Sciarra EC, Franco LJ, et al (2004) Primary prevention of type 2 diabetes through nutritional counseling. Diabetes Care 27(12):3019
14. Schneider H, Lischinski M, Jutzi E (1994) Prognosis of diabetic patients in Northeast Germany (in German). Z Arztl Fortbild (Jena) 88(11):925-930
15. Schwarz P (2003) Gründung der Arbeitsgemeinschaft Prävention des Typ-2-Diabetes der DDG. Diabetes Stoffwechsel 12(5):296
16. Schwarz P (2005) Targeted diabetes prevention in high risk groups: pro (in German). Dtsch Med Wochenschr 130(17):1103
17. Schwarz PEH (2005) Prävention des Diabetes mellitus Typ 2, Lebensstiländerung und medikamentöse Intervention. Notfall Hausarztmedizin 31(1):19-26
18. Torgerson JS, Hauptman J, Boldrin MN, et al (2004) XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27(1):155-161
19. Tuomilehto J, Lindstrom J, Eriksson JG, et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344(18):1343-1350
20. Turner RC, Cull CA, Frighi V, et al (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281(21):2005-2012
21. UK Prospective Diabetes Study Group (1994) UK Prospective Diabetes Study (UKPDS) XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11(6):534-544
22. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. [see comments]. BMJ 317(7160):703-713
23. Wenying J, Lixiang L, Zhiqing I, et al (2001) The preventative effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicentre prospective study. Chin J Endocrinol Metab 17:131-136
24. Zimmet P, Alberti KG, Shaw J (2001) Global and societal implications of the diabetes epidemic. Nature 414(6865):782-787
25. Zimmet P, Shaw J, Alberti KG (2003) Preventing type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view. Diabet Med 20(9):693-702